仁度生物(688193.SH)2025年度归母净利润950.91万元，同比扭亏为盈

Core Viewpoint - The company reported a revenue of 162 million yuan for the fiscal year 2025, reflecting a year-on-year decline of 8.62%, but achieved a net profit attributable to the parent company of 9.51 million yuan, marking a turnaround from previous losses [1] Group 1: Financial Performance - The company achieved a revenue of 162 million yuan, which is an 8.62% decrease compared to the previous year [1] - The net profit attributable to the parent company was 9.51 million yuan, indicating a return to profitability [1] Group 2: Operational Strategies - The company actively implemented the "quality improvement, efficiency enhancement, and return focus" action plan during the reporting period [1] - Measures such as cost reduction and expense control were taken to achieve a year-on-year decrease in period expenses [1] Group 3: Accounts Management - The company strengthened accounts receivable management and recovered some receivables from previous years [1] - According to relevant accounting standards and company policies, the company reversed some impairment losses during the reporting period [1]